Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.

MLA

Hamblin, Angela, et al. “Clinical Applicability and Cost of a 46-Gene Panel for Genomic Analysis of Solid Tumours: Retrospective Validation and Prospective Audit in the UK National Health Service.” PLoS Medicine, vol. 14, no. 2, Feb. 2017, pp. 1–26. EBSCOhost, https://doi.org/10.1371/journal.pmed.1002230.

APA

Hamblin, A., Wordsworth, S., Fermont, J. M., Page, S., Kaur, K., Camps, C., Kaisaki, P., Gupta, A., Talbot, D., Middleton, M., Henderson, S., Cutts, A., Vavoulis, D. V., Housby, N., Tomlinson, I., Taylor, J. C., & Schuh, A. (2017). Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service. PLoS Medicine, 14(2), 1–26. https://doi.org/10.1371/journal.pmed.1002230

Chicago

Hamblin, Angela, Sarah Wordsworth, Jilles M. Fermont, Suzanne Page, Kulvinder Kaur, Carme Camps, Pamela Kaisaki, et al. 2017. “Clinical Applicability and Cost of a 46-Gene Panel for Genomic Analysis of Solid Tumours: Retrospective Validation and Prospective Audit in the UK National Health Service.” PLoS Medicine 14 (2): 1–26. doi:10.1371/journal.pmed.1002230.